

~~WHAT IS CLAIMED IS:~~ CLAIMS

1. An antibody that specifically binds to sclerostin of SEQ ID NO: 1 and comprises a set of six CDRs set forth in SEQ ID NOs: 2-7, wherein the antibody comprises a heavy chain comprising the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8) at the C-terminus of the heavy chain.
2. The antibody of claim 1, wherein the antibody comprises a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 9 and a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 10.
3. The antibody of claim 1 ~~or claim 2~~, wherein the C-terminus of the heavy chain is amidated.
4. The antibody of ~~any one of claims~~ claim 1-3, wherein the C-terminus of both heavy chains comprises the amino acid sequence Pro-Ala-Arg-Gly (SEQ ID NO: 8).
5. The antibody of ~~claims~~ claim 4, wherein the C-terminus of both heavy chains is amidated.
6. The antibody of ~~any one of claims~~ claim 1-5, comprising the light chain amino acid sequence set forth in SEQ ID NO: 12 and the heavy chain amino acid sequence set forth in SEQ ID NO: 13.
7. The antibody of claim 1 ~~or claim 2~~, wherein the antibody comprises a sequence of amino acids comprising Pro-Ala-Arg-Gly-Lys (SEQ ID NO: 11) at the C-terminus of a heavy chain.
8. The antibody of claim 7, comprising the light chain amino acid sequence set forth in SEQ ID NO: 12 and the heavy chain amino acid sequence set forth in SEQ ID NO: 14.
9. A pharmaceutical composition comprising a population of antibodies of ~~any one of claims~~ claim 1-8 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising a mixture of antibodies that specifically bind to sclerostin of SEQ ID NO: 1 and a pharmaceutically acceptable carrier;
wherein about 3-5% of the antibodies in the composition are a population of antibodies of ~~any one of claims 1-8~~ claim 1.

11. The pharmaceutical composition of ~~claim 9 or~~ claim 10, wherein all or part of the population of antibodies comprise a single heavy chain comprising a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence.

12. The pharmaceutical composition of ~~claim 9 or~~ claim 10, wherein all or part of the population of antibodies comprise a heavy chain comprising a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence that is amidated.

13. The pharmaceutical composition of claim 12, wherein less than about 35% of the population of antibodies is singly amidated.

14. The pharmaceutical composition of claim 10, wherein all or part of the population of antibodies comprise a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence in both heavy chains.

15. The pharmaceutical composition of claim 14, wherein all or part of the population of antibodies comprising two heavy chains comprising a C-terminal Pro-Ala-Arg-Gly (SEQ ID NO: 8) sequence are amidated on both heavy chains.

16. The pharmaceutical composition of claim 15, wherein less than about 35% of the population of antibodies are amidated on both heavy chains.

17. The pharmaceutical composition of ~~any one of claims 9-16~~ claim 9, wherein less than about 35% of the population of antibodies comprise heavy chains that are not amidated.

18. The pharmaceutical composition of ~~any one of claims~~ claim 9-17, wherein about 33% of the population of antibodies are not amidated, about 33% of the population of antibodies comprise one amidated heavy chain, and about 33% of the population of antibodies comprise two amidated heavy chains.

19. The pharmaceutical composition of ~~any one of claims 9-18~~ claim 9, further comprising a calcium salt, an acetate buffer, a polyol and a surfactant.

20. The pharmaceutical composition of claim 19, wherein the calcium salt comprises calcium acetate.

21. The pharmaceutical composition of claim 19, wherein the acetate buffer comprises sodium acetate.

22. The pharmaceutical composition of claim 19, wherein the polyol comprises sucrose.

23. The pharmaceutical composition of claim 19, wherein the surfactant comprises polysorbate 20.

24. The pharmaceutical composition of claim ~~any one of claims 9-23~~9, further comprising 55 mM acetate, 13 mM calcium, 6.0 % (w/v) sucrose, 0.006% (w/v) polysorbate 20, pH 5.2.

~~25. — A method of increasing bone mineral density in a subject in need thereof comprising administering the composition of any one of claims 9-24 to the subject in an amount effective to increase bone mineral density in the subject.~~